8. JNJ-78436725 vaccine could be offered in a single doseDeveloper: Johnson & Johnson’s (NYSE:JNJ)
Description: The fourth vaccine in the U.S. to reach Phase 3 clinical trials, J&J’s Janssen Pharmaceuticals JNJ-78436725 vaccine could be the first single-dose vaccine to win an EUA from the FDA. Most of the COVID-19 vaccines in development require two. The company is, however, also testing a two-dose regimen for the vaccine in a Phase 3 trial.
The vaccine initially showed promise in inducing a neutralizing antibody response in rhesus macaques.
Development status: Johnson & Johnson is still testing the vaccine candidate in a Phase 3 trial, but the company aims to produce 1 billion doses of the vaccine by the end of 2021.